Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib vs platinum-pemetrexed in first-line ALK-positive NSCLC
CTR20140632Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ceritinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Nov 2014; status: terminated.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20140632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140632.